Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ganser

Showing results (51-60 of 378) with videos related to

Pageof 38
Sort By:
Pathologie-Biologie|May 7, 1998
Treatment with growth factors in myelodysplastic syndromesR G Geissler, P Schulte, A Ganser
Der Internist|August 27, 2013
[Thrombotic microangiopathy]G Beutel, J T Kielstein, A Ganser
Der Internist|November 11, 2011
[Current treatment options in acute myeloid leukemia]M Heuser, R F Schlenk, A Ganser
Wiener Medizinische Wochenschrift (1946)|January 1, 1996
[Patient education--support--help with decisions: ethical aspects in treatment of amyotrophic lateral sclerosis]J G Meran, M Hamm, A Ganser
International Journal of Clinical & Laboratory Research|January 1, 1992
Interleukin-3 in the treatment of myelodysplastic syndromesA Ganser, O G Ottmann, D Hoelzer
Stem Cells (Dayton, Ohio)|November 1, 1993
Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implicationsA Ganser, O G Ottmann, D Hoelzer
Annals of Hematology|December 17, 2002
In vitro response of myelodysplastic megakaryocytopoiesis to megakaryocyte growth and development factor (MGDF)M Faulhaber, B Wörmann, A Ganser, et al.
Analytical Biochemistry|March 30, 1999
Differential quantitation of alternatively spliced messenger RNAs using isoform-specific real-time RT-PCRS Kafert, J Krauter, A Ganser, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 1, 1997
Safety, feasibility and therapeutic activity of intrapleural autologous lymphocyte conditioned medium followed by systemic recombinant interleukin-2 and interferon-alpha in a patient with malignant pleural mesotheliomaS Duensing, H Hamm, A Ganser, et al.
Annals of Hematology|October 10, 2002
Evaluating the prognosis of patients with myelodysplastic syndromesC Aul, A Giagounidis, U Germing, et al.
Pageof 38

Showing results (51-60 of 378) with videos related to

Sort By:
Pageof 38
Pathologie-Biologie|May 7, 1998
Treatment with growth factors in myelodysplastic syndromesR G Geissler, P Schulte, A Ganser
Der Internist|August 27, 2013
[Thrombotic microangiopathy]G Beutel, J T Kielstein, A Ganser
Der Internist|November 11, 2011
[Current treatment options in acute myeloid leukemia]M Heuser, R F Schlenk, A Ganser
Wiener Medizinische Wochenschrift (1946)|January 1, 1996
[Patient education--support--help with decisions: ethical aspects in treatment of amyotrophic lateral sclerosis]J G Meran, M Hamm, A Ganser
International Journal of Clinical & Laboratory Research|January 1, 1992
Interleukin-3 in the treatment of myelodysplastic syndromesA Ganser, O G Ottmann, D Hoelzer
Stem Cells (Dayton, Ohio)|November 1, 1993
Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implicationsA Ganser, O G Ottmann, D Hoelzer
Annals of Hematology|December 17, 2002
In vitro response of myelodysplastic megakaryocytopoiesis to megakaryocyte growth and development factor (MGDF)M Faulhaber, B Wörmann, A Ganser, et al.
Analytical Biochemistry|March 30, 1999
Differential quantitation of alternatively spliced messenger RNAs using isoform-specific real-time RT-PCRS Kafert, J Krauter, A Ganser, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 1, 1997
Safety, feasibility and therapeutic activity of intrapleural autologous lymphocyte conditioned medium followed by systemic recombinant interleukin-2 and interferon-alpha in a patient with malignant pleural mesotheliomaS Duensing, H Hamm, A Ganser, et al.
Annals of Hematology|October 10, 2002
Evaluating the prognosis of patients with myelodysplastic syndromesC Aul, A Giagounidis, U Germing, et al.
Pageof 38